- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Aug 12, 2023
Regulation
Aug. 11 Quick Takes: Janssen gains prostate cancer approval
Plus: Atreca scraps lead program, turns to ADCs and updates from ALX Oncology, Hansoh-Antengene, Foghorn, Galera, Cascade
BioCentury | Mar 16, 2022
Deals
March 15 Quick Takes: Blackstone backs Sanofi’s multiple myeloma trial
Plus: Keytruda, Lynparza combo misses, pandemic antiviral initiative launches and updates from Eisai, Biogen and more
BioCentury | Jan 25, 2020
Product Development
Radiotherapy blasts forward
Who's doing what in next-generation targeted radiotherapies for cancer
BioCentury | Sep 30, 2019
Clinical News
Dual ESMO readouts could expand Lynparza's reach to new patients
BioCentury | Sep 14, 2018
Emerging Company Profile
Laekna’s jumping off place
Why Laekna Therapeutics opted to start with a trio of Novartis compounds
Items per page:
1 - 10 of 165